SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Welcure Drugs & Pharmaceuticals Ltd (524661)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524661 NSE: Trading | Small Cap | Welcure Drugs&Pharma Share Price

₹0.25 -0.01 (-3.85%)

As on 29-Jun'26 16:59

Welcure Drugs & Pharmaceuticals Ltd (524661)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524661 NSE: Trading | Small Cap | Welcure Drugs&Pharma Share Price

₹0.25 -0.01 (-3.85%)

As on 29-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹32 Cr.
Current Price
₹0.3
52-Week Low / High
₹0 / 1
TTM EPS
₹-0
TTM Sales
₹366 Cr.
Book Value per Share
₹0.8
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
37.3
Price to Book (P/B)
0.33
Lower than its 5-year historical median
Price to Sales (P/S)
0.09
Higher than its 3-year historical median
EV/EBITDA
-28.37
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
4.18%
Outperforms industry median
Return on Capital Employed (ROCE)
2.53%
Underperforms industry median
Return on Assets (ROA)
1.62%
Operating Profit Margin
3.9%
Net Profit Margin
8.84%
Gross Profit Margin
11.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
0.00%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-27 Cr.
Equity
₹123.6 Cr.
Face Value
₹1
All Time Low / High
₹0.03 / 3.64

Welcure Drugs & Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Welcure Drugs & Pharmaceuticals Ltd a good quality company?
Welcure Drugs & Pharmaceuticals Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Welcure Drugs & Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Welcure Drugs & Pharmaceuticals Ltd vs industry peers?
Welcure Drugs & Pharmaceuticals Ltd revenue CAGR is 214.33%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Welcure Drugs & Pharmaceuticals Ltd?
Promoters hold 0.00% of the Welcure Drugs & Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Welcure Drugs & Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 9.2% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Welcure Drugs & Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0%108.9%-65.5%18.2%-48.9%131.9%29.1%12.7%-12.2%2.5%-
Value Creation
Index
NA6.8-5.70.3-4.58.41.1-0.1-1.9-0.8-

Growth Parameters

Sales 0.10.10.10.10.10.10.10024.6366
Sales YoY Gr.--10%-44.4%60%0%62.5%-15.4%-100%NANA-
Adj EPS 00-00-0000-00-0
YoY Gr.--100%NANANANANANA-200%NA-
BVPS (₹) 00000000.10.10.80.8
Adj Net
Profit
0.10-00-00.100.1-0.22.2-5
Cash Flow from Ops. -0.10-00-0000.1-0.1-222-
Debt/CF from Ops. 000000000-0.6-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 84.3%214.3%506.6%NA
Adj EPS 8%NANANA
BVPSNANA336.2%822.2%
Share Price 8.6% -0.8% -12.3% -78.8%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-274.3108.6-65.817.8-49.5131.72911.4-124.2-5
Op. Profit
Mgn %
32.430.9-412.9-11.641.322.5003.911.6
Net Profit
Mgn %
85.630.8-38.84.9-11.441.422.5008.8-1.4
Debt to
Equity
0000000001.2-
Working Cap
Days
286010959766198001,993188
Cash Conv.
Cycle
0000000001,20559

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales0.100.090.050.080.080.130.110024.55
Operating Expenses + 0.070.060.070.080.090.080.080.130.2323.58
Manufacturing Costs0000000000.01
Material Costs00000000020.50
Employee Cost 00000000.030.080.10
Other Costs 0.070.060.070.080.090.080.080.100.152.97
Operating Profit 0.030.03-0.020-0.010.060.02-0.13-0.230.97
Operating Profit Margin (%) 32.4%30.9%-41.0%2.9%-11.6%41.3%22.5%--3.9%
Other Income + 0.050000000.240.091.91
Exceptional Items 0000000000
Interest 0000000000.09
Depreciation 000000000.040.01
Profit Before Tax 0.090.03-0.020-0.010.060.020.10-0.172.78
Tax 0000000000.61
Profit After Tax 0.090.03-0.020-0.010.060.020.10-0.172.17
PAT Margin (%) 85.6%30.8%-38.8%4.9%-11.4%41.4%22.5%--8.8%
Adjusted EPS (₹)0.00.00.00.00.00.00.00.0-0.00.0
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Welcure Drugs&Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 0.010.040.020.020.010.070.091.521.34102.51
Share Capital 12.1212.1212.1212.1212.1212.1212.1213.4413.44112.44
Reserves -12.11-12.08-12.10-12.09-12.10-12.05-12.03-11.92-12.10-9.93
Debt +000000000123.20
Long Term Debt000000000123.20
Short Term Debt0000000000
Minority Interest0000000000
Trade Payables0000000002.90
Others Liabilities 0000.010.01000.010.0338.37
Total Liabilities 0.020.040.020.030.020.070.101.531.37266.98

Fixed Assets

Net Fixed Assets +00000000.060.020.03
Gross Block00000000.060.060.08
Accumulated Depreciation000000000.040.05
CWIP 0000000000
Investments 00000000.1700
Inventories000000000143.52
Trade Receivables00000000018.95
Cash Equivalents 0.010.020.010.010.010.050.0700.020.13
Others Assets 0.010.020.010.010.020.030.031.311.33104.35
Total Assets 0.020.040.020.030.020.070.101.531.37266.98

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + -0.050.02-0.010-0.010.040.020.11-0.13-222.03
PBT 0.090.03-0.020-0.010.060.020.10-0.172.78
Adjustment -000000000.040.01
Changes in Working Capital -0.13-0.010.01-0-0-0.01-0.010.010.01-224.82
Tax Paid 0000000000
Cash Flow From Investing Activity + 0.0300000000.17-0.06
Capex 000000000-0.02
Net Investments 000000000.170
Others 0.0300000000-0.05
Cash Flow From Financing Activity + 0000000-0.17-0.02222.20
Net Proceeds from Shares 00000001.32099
Net Proceeds from Borrowing 000000000123.20
Interest Paid 0000000000
Dividend Paid 0000000000
Others 0000000-1.49-0.020
Net Cash Flow -0.020.02-0.010-0.010.040.02-0.070.020.11

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)0108.61-65.817.83-49.46131.7429.0312.69-12.244.18
ROCE (%)0108.91-65.4618.22-48.94131.9429.1212.69-12.242.53
Asset Turnover Ratio2.663.071.512.993.032.731.24000.18
PAT to CFO Conversion(x)-0.560.67N/AN/AN/A0.6711.1N/A-102.32
Working Capital Days
Receivable Days000000000281.70
Inventory Days0000000002,133.90
Payable Days00000000051.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Welcure Drugs & Pharmaceuticals Ltd FAQs

The current trading price of Welcure Drugs&Pharma on 29-Jun-2026 16:59 is ₹0.25.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Jun-2026 the market cap of Welcure Drugs&Pharma stood at ₹32.13 Cr

The latest P/E ratio of Welcure Drugs&Pharma as of 28-Jun-2026 is 0.00.

The latest P/B ratio of Welcure Drugs&Pharma as of 28-Jun-2026 is 0.33.

The 52-week high of Welcure Drugs&Pharma is ₹1.36 and the 52-week low is ₹0.23.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Welcure Drugs&Pharma is ₹366 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Welcure Drugs & Pharmaceuticals Ltd is a average quality company.

The key valuation ratios of Welcure Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Welcure Drugs & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Welcure Drugs & Pharmaceuticals Ltd

Welcure Drugs & Pharmaceuticals Ltd. (WDPL)  was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992.

Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified Company. It has to its credit the most modern and sophisticated manufacturing facilities of International Standards which include ultramodern plant, machinery and equipment, own R & D, in house testing laboratory and captive power generation.

Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups.  The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals.  The products of the company have already been well accepted in the domestic markets and the Company has an established customer base.

In March 2000 WDPL entered into a five-year agreement with Bihar Drugs and Chemicals Ltd (BDCL), a subsidiary of Bihar State Pharmaceutical and Chemical Development Corporation Ltd, for manufacturing various pharmaceutical pro ducts (both generic as well as branded) for the latter on loan licence basis. WDPL manufactures the drugs in tablet, capsule and syrup form at its facilities situated in Bhiwadi (Rajasthan).

The Company’s principal activity is to manufacture pharmaceutical products. The products of the Company include tablets, capsules, liquid orals and dry syrups.

Product range of the company includes:

Welcure manufactures a large variety of pharmaceutical formulations, covering almost all ailments, about 250 in numbers. Some of our known products include:

  • Brucure
  • Diclo-plus, Dimcinplus
  • Nimesulide
  • Nimagyltd (tongue dissolvent)
  • Ibucure & Relaxon Forte
  • Coldrest, Alert10004 Coldhistex
  • Cezen & Cezen Forte, Cezen CD
  • Kuffwel
  • X-Dryl, X-Dryl Forte
  • Renact DM
  • Renact DC
  • Diaroban
  • Welcee (Chewable Tab.)
  • Calbiplex
  • Wormicide
  • X-Clox
  • Weloxy-L
  • Welquin
  • Nortin, Cipcin-TNZ
  • Sarvo
  • B-Rest
  • Lopcure
  • Rifampicin, Ethambutol, Rifa-Z
  • Weloxy-P,Amicure-P
  • Norkid
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: